Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...
Following the transaction, Borgeson directly owns 6,429,863 shares of Recursion Pharmaceuticals. The company, while holding more cash than debt with a current ratio of 4.6, is quickly burning through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results